Aptinyx Conducts Phase 2 Trials of Investigational Therapy for Neuropathic Pain and Fibromyalgia

Aptinyx Conducts Phase 2 Trials of Investigational Therapy for Neuropathic Pain and Fibromyalgia
The biopharmaceutical company Aptinyx recently announced updates regarding its two Phase 2 clinical trials evaluating the company’s lead therapy candidate, NYX-2925. This therapy aims to treat pain associated with fibromyalgia and neuropathic pain associated with diabetic peripheral neuropathy (DPN). NYX-2925 is a modulator of the N-methyl-D-aspartate (NMDA) receptor, which is involved in the process that causes chronic pain. The investigational therapy binds to a distinct, recently discovered site on the NMDA receptor to modulate NMDA-receptor-channel opening and enhance synaptic plasticity. This unique method was shown to be effective in animal models of several pain conditions and had a favorable safety profile. In a previous Phase 1 clinical study (NCT02834741) in healthy subjects, NYX-2925 was found to be well-tolerated across a wide dose range. “The Phase 1 study clearly demonstrated that NYX-2925 has highly predictable pharmacokinetics and is well-tolerated at doses that far exceed anticipated therapeutic doses. Therefore, we have advanced NYX-2925 into Phase 2 development for neuropathic pain associated with diabetic peripheral neuropathy, a condition in which patients struggle to manage their pain effectively with currently available therapeutic options,” Torsten Madsen, MD, PhD, Aptinyx’s chief medical officer, said in a press release. “Our preclinical research also supports studying NYX- 2925 in several other chronic pain conditions, including fibromyalgia,” Madsen added. Researchers will soon start recruit
Subscribe or to access all post and page content.